MX354828B - Polvos secos de cationes metálicos monovalentes para inhalación. - Google Patents

Polvos secos de cationes metálicos monovalentes para inhalación.

Info

Publication number
MX354828B
MX354828B MX2013003478A MX2013003478A MX354828B MX 354828 B MX354828 B MX 354828B MX 2013003478 A MX2013003478 A MX 2013003478A MX 2013003478 A MX2013003478 A MX 2013003478A MX 354828 B MX354828 B MX 354828B
Authority
MX
Mexico
Prior art keywords
dry powders
monovalent metal
inhalation
metal cation
cation dry
Prior art date
Application number
MX2013003478A
Other languages
English (en)
Spanish (es)
Other versions
MX2013003478A (es
Inventor
Michael M Lipp
Jean C Sung
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/049435 external-priority patent/WO2012030664A1/en
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of MX2013003478A publication Critical patent/MX2013003478A/es
Publication of MX354828B publication Critical patent/MX354828B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
MX2013003478A 2010-09-29 2011-09-29 Polvos secos de cationes metálicos monovalentes para inhalación. MX354828B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38788310P 2010-09-29 2010-09-29
US201161481879P 2011-05-03 2011-05-03
PCT/US2011/049435 WO2012030664A1 (en) 2010-08-30 2011-08-26 Dry powder formulations and methods for treating pulmonary diseases
PCT/US2011/053829 WO2012044736A1 (en) 2010-09-29 2011-09-29 Monovalent metal cation dry powders for inhalation

Publications (2)

Publication Number Publication Date
MX2013003478A MX2013003478A (es) 2013-10-30
MX354828B true MX354828B (es) 2018-03-22

Family

ID=45002202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003478A MX354828B (es) 2010-09-29 2011-09-29 Polvos secos de cationes metálicos monovalentes para inhalación.

Country Status (12)

Country Link
US (6) US9642798B2 (OSRAM)
EP (2) EP2621484A1 (OSRAM)
JP (3) JP5877204B2 (OSRAM)
KR (2) KR20180122475A (OSRAM)
CN (2) CN107096014B (OSRAM)
AU (2) AU2011308865B2 (OSRAM)
BR (1) BR112013007304B1 (OSRAM)
CA (2) CA3086367A1 (OSRAM)
IL (4) IL286573B (OSRAM)
MX (1) MX354828B (OSRAM)
RU (2) RU2017144619A (OSRAM)
WO (1) WO2012044736A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
CN107096014B (zh) * 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CN104487075A (zh) * 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
EP3203985A1 (en) * 2014-10-08 2017-08-16 Pulmatrix Operating Company, Inc. Improved stability of dry powders containing tiotropium and amino acid
CA2963666A1 (en) * 2014-10-08 2016-04-14 Pulmatrix Operating Company, Inc. Formulations containing tiotropium, amino acid and acid and methods thereof
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
PT108885B (pt) 2015-10-12 2019-02-13 Hovione Farm S A Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos
EP4079291A1 (en) * 2016-01-29 2022-10-26 MannKind Corporation Dry powder inhaler
CN110062765A (zh) 2016-10-31 2019-07-26 维克特拉有限公司 包括il-13抗体的可吸入粉末组合物
CN111712233A (zh) * 2018-02-26 2020-09-25 株式会社新日本科学 粉末制剂、药筒及装置
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
CN110161142A (zh) * 2019-06-11 2019-08-23 珠海瑞思普利生物制药有限公司 一种表征干粉吸入制剂在呼吸系统空气动力学的仿真装置
US11925907B2 (en) 2019-07-22 2024-03-12 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
WO2021202429A1 (en) * 2020-03-28 2021-10-07 Esrail Medical Corp. Methods and compositions for treatment of covid-19
CN114306220A (zh) * 2020-10-09 2022-04-12 刘志 吸入制剂及其制备方法和应用
WO2022109059A1 (en) * 2020-11-18 2022-05-27 Bend Research, Inc. Inhalable dry powder formulations comprising angiogenesis inhibitors
AU2021409569A1 (en) * 2020-12-23 2023-06-01 Amgen Inc. Methods and systems for selecting conditions for making inhalation formulations
CA3197954A1 (en) 2022-04-26 2023-10-26 Adam Campbell Nasal rinse compositions and methods
WO2024046582A1 (en) * 2022-09-02 2024-03-07 Liita Care Aps Pharmaceutical dry powder composition and methods for treating respiratory tract infections

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4085893A (en) 1974-03-20 1978-04-25 Durley Iii Benton A Ultrasonic humidifiers, atomizers and the like
US4193009A (en) 1976-01-26 1980-03-11 Durley Benton A Iii Ultrasonic piezoelectric transducer using a rubber mounting
JPS5550437U (OSRAM) 1978-09-28 1980-04-02
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
KR900001873B1 (ko) 1984-06-14 1990-03-26 산요덴끼 가부시끼가이샤 초음파 가습장치
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
FI82808C (fi) 1987-12-31 1991-04-25 Etelae Haemeen Keuhkovammayhdi Ultraljudfinfoerdelningsanordning.
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US4921639A (en) 1988-11-09 1990-05-01 Bernard Chiu Ultrasonic humidifier
US4881541A (en) 1988-12-21 1989-11-21 The Regents Of The University Of California Vaporizer for an anesthetic having a vapor pressure about one atmosphere
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5571535A (en) 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
JPH05123398A (ja) 1991-11-06 1993-05-21 Tsunemasa Kamiyama 咽喉保護吸入剤並びに吸入器具
GB2265845B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5292127C1 (en) * 1992-10-02 2001-05-22 Arcade Planet Inc Arcade game
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
ATE218132T1 (de) 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
EP0820277B1 (en) 1995-04-14 2005-01-26 Nektar Therapeutics Powdered pharmaceutical formulations having improved dispersibility
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11503352A (ja) 1995-04-14 1999-03-26 グラクソ、ウェルカム、インコーポレーテッド プロピオン酸フルチカゾン用計量投与用吸入器
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
RU2140273C1 (ru) * 1996-11-06 1999-10-27 Закрытое акционерное общество "АЭРОМЕД" Способ лечения простудных заболеваний
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999016421A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
EP1067839A1 (en) 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
FR2780285B1 (fr) 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP3312216B2 (ja) 1998-12-18 2002-08-05 オムロン株式会社 噴霧装置
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
AU4979700A (en) 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
CA2383491A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
EP1210067A2 (en) * 1999-08-25 2002-06-05 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
EP1666028B1 (en) 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
AU772096B2 (en) 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6637432B2 (en) 2000-05-09 2003-10-28 Iep Pharmaceutical Devices Inc. Inhalation actuated device
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
WO2002009574A2 (en) 2000-08-01 2002-02-07 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatment of the respiratory tract
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
AU2002245181B2 (en) 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6660249B2 (en) 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
WO2002060468A2 (en) 2001-01-30 2002-08-08 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6511050B2 (en) 2001-05-02 2003-01-28 Dynamo Aviation, Inc. Humidifier
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
JP2003074919A (ja) 2001-08-31 2003-03-12 Sunbow Precision Co Ltd 複合式加湿器
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030203930A1 (en) 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
AU2002352836B2 (en) * 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
CN1596120A (zh) 2001-11-26 2005-03-16 第一三得利制药株式会社 经鼻吸收用药物组合物
US6851626B2 (en) 2002-01-07 2005-02-08 Aerogen, Inc. Methods and devices for nebulizing fluids
GB2384198B (en) 2002-01-18 2005-03-02 Profile Drug Delivery Ltd Nebulizer metering
GB0217199D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20030232019A1 (en) 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
LT2630954T (lt) 2002-03-20 2017-01-25 Civitas Therapeutics, Inc. Levodopos įvedimas į plaučius
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0209782D0 (en) 2002-04-29 2002-06-05 Glaxo Group Ltd Medicament dispenser
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
CA2488976C (en) 2002-06-28 2009-08-25 Advanced Inhalation Research, Inc. Inhalable epinephrine
US6916001B2 (en) * 2002-07-10 2005-07-12 Lowell Thomas Pugh, Jr. Concrete form apparatus and method for assembly thereof
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
EP1556018A1 (en) 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
CN101804200A (zh) 2002-11-22 2010-08-18 余芒 广谱抗病毒的治疗和预防
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (zh) 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
NZ543201A (en) 2003-05-01 2007-05-31 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
US7883031B2 (en) 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US7195179B2 (en) 2003-06-01 2007-03-27 Piezo Technologies Piezoelectric mist generation device
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR20050056622A (ko) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 플레쉬롬 다운로드 장치
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
WO2005079755A2 (en) 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
CA2561993A1 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20070275091A1 (en) 2004-03-30 2007-11-29 Malcolm King Compositions And Methods For Improved Mucus Function
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
JP2008504330A (ja) 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴ脂質由来医薬組成物
DE102004031863B3 (de) 2004-07-01 2006-03-09 Airbus Deutschland Gmbh Vorrichtung zur Fixierung von insbesondere flächenhaften Werkstücken mit einer Anlagefläche
CA2574958A1 (en) 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1796677A4 (en) 2004-09-07 2009-07-08 Smithkline Beecham Corp PROCESS FOR ACTIVATION OF TRPV4 CHANNEL RECEPTORS BY AGONISTS
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006084131A2 (en) 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
US8429992B2 (en) 2005-02-10 2013-04-30 Borgwarner Inc. Power flow configuration for dual clutch transmission mechanism
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
US20060229366A1 (en) 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
CN101247898B (zh) 2005-05-05 2011-01-26 普马特里克斯公司 超音波气雾产生器
JP2008540680A (ja) * 2005-05-18 2008-11-20 プルマトリックス インコーポレイテッド 粘膜内壁の生物物理学的な性質を変化させる製剤
WO2006125132A2 (en) 2005-05-18 2006-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2007053526A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of trpv2
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
WO2007126871A1 (en) 2006-03-29 2007-11-08 Array Biopharma Inc. P38 inhibitors and methods of use thereof
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
WO2008065666A2 (en) 2006-11-29 2008-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Uses of incensole, incensole acetate and derivatives thereof
US8501255B2 (en) 2006-12-14 2013-08-06 Purac Biochem B.V. Particulate composition comprising calcium lactate and calcium citrate microparticles
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP2011495A1 (en) 2007-07-03 2009-01-07 Sygnis Bioscience GmbH & Co. KG Use of piperine and derivatives thereof for the therapy of neurological conditions
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
GB0719518D0 (en) 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
JP5385299B2 (ja) 2007-12-05 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ジベンゾアゼピンおよびジベンゾオキサゼピン・ｔｒｐａ１アゴニスト
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
NO2252275T3 (OSRAM) 2008-02-13 2018-04-28
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
AU2009246217B2 (en) 2008-05-15 2013-01-10 Novartis Ag Pulmonary delivery of a fluoroquinolone
EP2323640A2 (en) 2008-08-04 2011-05-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
WO2010111641A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
ATE538774T1 (de) 2009-03-26 2012-01-15 Pulmatrix Inc Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
WO2010111640A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
EP2410981B2 (en) * 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2754684A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CA2767646C (en) 2009-07-10 2019-01-29 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9061352B2 (en) * 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN107096014B (zh) * 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
CN104487075A (zh) * 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
RU2766086C2 (ru) * 2016-10-14 2022-02-07 Пулматрикс Оперэйтинг Компани, Инк. Противогрибковые сухие порошки

Also Published As

Publication number Publication date
AU2016269398B2 (en) 2018-10-04
KR101915241B1 (ko) 2018-11-06
CA2812414A1 (en) 2012-04-05
AU2016269398A1 (en) 2016-12-22
KR20180122475A (ko) 2018-11-12
BR112013007304B1 (pt) 2021-12-14
WO2012044736A1 (en) 2012-04-05
IL225398A (en) 2017-12-31
MX2013003478A (es) 2013-10-30
IL286573A (en) 2021-10-31
US20150231066A1 (en) 2015-08-20
IL256360A (en) 2018-02-28
US20210121399A1 (en) 2021-04-29
CA2812414C (en) 2020-09-22
AU2011308865A1 (en) 2013-04-18
US20190388342A1 (en) 2019-12-26
JP2016065107A (ja) 2016-04-28
JP6392422B2 (ja) 2018-09-19
AU2011308865B2 (en) 2017-01-05
US9642798B2 (en) 2017-05-09
RU2013118453A (ru) 2014-11-10
RU2640921C2 (ru) 2018-01-12
CA3086367A1 (en) 2012-04-05
US20130266653A1 (en) 2013-10-10
CN103228273A (zh) 2013-07-31
EP2621484A1 (en) 2013-08-07
JP5877204B2 (ja) 2016-03-02
CN107096014A (zh) 2017-08-29
JP6186458B2 (ja) 2017-08-23
US11173115B2 (en) 2021-11-16
IL271976A (en) 2020-02-27
KR20130098370A (ko) 2013-09-04
US20240156728A1 (en) 2024-05-16
IL286573B (en) 2022-08-01
EP4008326A1 (en) 2022-06-08
US10376465B2 (en) 2019-08-13
IL225398A0 (en) 2013-06-27
CN107096014B (zh) 2022-07-15
JP2017190353A (ja) 2017-10-19
RU2017144619A (ru) 2019-02-20
JP2013540123A (ja) 2013-10-31
IL256360B (en) 2020-03-31
BR112013007304A2 (pt) 2016-07-05
CN103228273B (zh) 2017-04-05
RU2017144619A3 (OSRAM) 2021-06-02
US20170143624A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MX354828B (es) Polvos secos de cationes metálicos monovalentes para inhalación.
MX354829B (es) Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
EA201490047A1 (ru) Ингаляционные фармацевтические композиции
PH12015500684A1 (en) An inhaler
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
MX358061B (es) Dispositivos de suministro nasal.
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2012031603A3 (en) Airway administration of angiogenesis inhibitors
PL2670395T3 (pl) Suche proszkowe formulacje cząstek, które zawierają dwa lub więcej składników aktywnych do leczenia obturacyjnych lub zapalnych chorób dróg oddechowych
MX382999B (es) Polvos pulmonares de ultra baja densidad
MX2015013845A (es) Polvos secos de tiotropio.
EA201490991A1 (ru) Композиции, способы и устройства для респираторной доставки двух или более активных средств
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
MX2021005056A (es) Medicamentos inhalables.
MX2018015969A (es) Formulaciones tensoactivas para inhalacion.
UA118192C2 (uk) Противірусна фармацевтична композиція
ZA202004310B (en) Surfactant formulations for inhalation
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
ZA202004309B (en) Surfactant formulations for inhalation
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
MX2023008323A (es) Polvos secos de cationes metalicos monovalentes para inhalacion
MY171853A (en) Sphingomyelin-containing supplement
WO2020055356A3 (en) Inhalation compositions comprising anti-bacterial agents

Legal Events

Date Code Title Description
FG Grant or registration